{"entity":{"id":"nct04496349","kind":"trial","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","aka":[],"tldr":"A phase 2 trial of APG-115 in hodgkin lymphoma, run by Ascentage Pharma Group Inc., now recruiting.","summary":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL is a phase 2 interventional study registered as NCT04496349 by Ascentage Pharma Group Inc., with 78 participants planned, started 2021-07-12 and due to reach its primary completion in 2026-05-31. Interventions recorded: APG-115 and APG-2575.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04496349","url":"https://clinicaltrials.gov/study/NCT04496349"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04496349","phase":"2","setting":"A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).","sponsor":"Ascentage Pharma Group Inc.","enrolled":78,"outcomes":[]},"route":"/trials/nct04496349/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}